drugset / Trial / NCT04985136
A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy and safety of Camrelizumab Combined with Rivoceranib Mesylate versus Investigator's Choice of Regimen in Treatment of Patients with Hepatocellular Carcinoma (HCC)
Timeline
- Start
- 2021-09-26
- Primary completion
- 2021-12-29
- Completion
- 2021-12-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Comparator | Regorafenib | Small molecule | 160 mg | Oral |
| Comparator | Rivoceranib | Small molecule | 250 mg | Oral |
| Comparator | Rivoceranib | Small molecule | 750 mg | Oral |
| Comparator | Sorafenib | Small molecule | 400 mg | Oral |